- EMA CHMP issued a negative opinion on Omeros (OMER) narsoplimab for TA‑TMA, citing trial design, concomitant meds, conduct and pediatric data gaps; Omeros plans re‑examination. Shares fell premarket.
- HC Wainwright cut Omeros (OMER) price target to $33 from $40. No other updates provided. Traders note the lowered target and unchanged company disclosures.
TradingView
Key facts: CHMP Rejects Omeros' Narsoplimab; Price Target Cut to $33
- Sources
- TradingView
- Markets
- Stocks
- Active symbols
- NASDAQ:OMER
- Language
- English
EMA CHMP issued a negative opinion on Omeros (OMER) narsoplimab for TA‑TMA, citing trial design, concomitant meds, conduct and pediatric data gaps; Omeros plans re‑examination. Sha